Venlo, the Netherlands, Sept. 25, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of its eco-friendlier QIAwave product line with the ...

QIAGEN has historically allocated global production capacity to manufacture RNA nucleic extraction reagents to supply about 1.5 million patient tests on a monthly basis.

new user-friendly and easy extraction kits and use of DNA/RNA in profiling new diseases causing microorganisms are expected to boost the market. In July 2023, QIAGEN launched the QIAseq Normalizer ...

Qiagen, an international company that makes a critical part of diagnostic tests for the novel coronavirus, announced this week that it is ramping up production of their RNA extraction kits in the ...

Venlo, the Netherlands, Sept. 25, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of its e Tuesday, 02 January 2024 12:17 GMT عربي ...

Goal to reach global capacity for RNA nucleic extraction ... June 2020 and to reach capacity for 20 million monthly patient tests by end of 2020 Welcomes FDA and CDC expansion of QIAGEN kits ...

Goal to reach global capacity for RNA nucleic extraction workflows for over 10 million patient tests a month by end of June 2020 and to reach capacity for 20 million monthly patient tests by end of ...

* QIAGEN NV - RAMPING UP GLOBAL PRODUCTION CAPACITY FOR RNA EXTRACTION KITS FOR USE IN DETECTION OF SARS-COV-2 CORONAVIRUS * QIAGEN - RAMPING UP PRODUCTION CAPACITY FOR REAGENTS TO SUPPORT A LEVEL ...